Kiora Pharmaceuticals, Inc.
KPRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. The company carries a $11.3M market cap, placing it firmly in the micro-cap category. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Market Cap
$11.3M
Beta
-0.33
P/E (TTM)
—
P/E (Fwd)
-1.14
EPS (TTM)
$-2.41
EPS (Fwd)
$-2.23
ROE
-56.4%
ROA
-21.9%
Cash
$16.8M
Total Debt
$333,022
Free CF
-$6.4M
52W Change
-5.1%
Annual Financials
Cash vs Debt
Where KPRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KPRX finished 7.47% above its 150-day moving average ($2.41) and 11.64% above its 200-day moving average ($2.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KPRX overbought or oversold?
At the September 3, 2026 close, KPRX's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kiora Pharmaceuticals, Inc. holds $16.8M in cash against $333K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Kiora Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, KPRX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KPRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.